B. Riley analyst Neil Chatterji lowered the firm’s price target on Procept BioRobotics to $55 from $60 and keeps a Buy rating on the shares. Procept reported a top-line beat for Q3, and the company raised its top-line guidance to $133.5M, with management having high confidence in the sales funnel, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRCT:
- Procept BioRobotics raises FY23 revenue view to $133.5M from $131M
- Procept BioRobotics reports Q3 EPS (51c), consensus (53c)
- PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
- PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023
- Wayfair upgraded, JD.com downgraded: Wall Street’s top analyst calls
